1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pathology Analysis & Statistics 2022 - Europe

Pathology Analysis & Statistics 2022 - Europe

1-30 of about 100 reports

Market Access Impact: Renal Cell Carcinoma (EU5) 2018

  • $ 5865
  • April 2018
  • 1 pages

Market barriers affect 14 percent of RCC prescriptions in Europe. Is your brand losing out? Despite market barriers only affecting 14 percent of all renal cell carcinoma (RCC) prescriptions in Europe, ...

  • Europe
  • Renal Cancer
  • Targeted Therapy
  • Industry analysis

Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

  • $ 5865
  • April 2018
  • 1 pages

Market barriers affect a fifth of oral diabetes treatment prescriptions in Europe. Is your brand losing out? Market barriers affect over a fifth of all oral type 2 diabetes mellitus (T2DM) prescriptions ...

  • Europe
  • Spain
  • Type 2 Diabetes
  • Industry analysis

NPS+ Haemophilia B (EU5) 2018

  • $ 2924
  • February 2018
  • 1 pages

Why are some EU5 Haemophilia B brands standing out more than others? There are various options available to EU5 haematologists treating haemophilia B. Clearly some of these options are achieving greate ...

  • Europe
  • World
  • Blood Disease
  • Industry analysis

NPS+ Renal Cell Carcinoma (EU5) 2018

  • $ 2924
  • February 2018
  • 1 pages

Why are some EU5 RCC brands standing out more than others? There are various options available to EU5 oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greate ...

  • Europe
  • World
  • Health Care Provider
  • Targeted Therapy
  • Industry analysis

NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]

  • $ 2924
  • February 2018
  • 1 pages

Why are some EU5 HCV brands standing out more than others? There are various options available to EU5 infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection ...

  • Europe
  • World
  • Hepatitis Treatment
  • Hepatitis
  • Industry analysis

NPS+ HIV (EU5) 2018

  • $ 2924
  • February 2018
  • 1 pages

Why are some EU5 HIV brands standing out more than others? There are various options available to EU5 infectious disease specialists treating HIV. Clearly some of these options are achieving greater levels ...

  • World
  • Europe
  • Antiviral
  • Infectious Disease
  • Industry analysis

Market Access Impact: Ulcerative Colitis (EU5) 2018

  • $ 5865
  • February 2018
  • 1 pages

Market barriers affect 12% of ulcerative colitis prescriptions. Is your brand losing out? In the EU5, market barriers affect 12% of all ulcerative colitis prescriptions, with the top brand way ahead of ...

  • Spain
  • France
  • Autoimmune Disease
  • Industry analysis

Market Access Impact: Psoriasis (EU5) 2018

  • $ 5865
  • February 2018
  • 1 pages

Market barriers affect just over a fifth of psoriasis prescriptions. Is your brand losing out? In the EU5, market barriers affect just over a fifth of all psoriasis prescriptions, with the top brand way ...

  • Spain
  • France
  • Autoimmune Disease
  • Monoclonal Antibody
  • Industry analysis

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

  • $ 6948
  • March 2018
  • 1 pages

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team ...

  • Spain
  • France
  • Renal Cancer
  • Health Care Provider
  • Industry analysis

Pricing and Reimbursement in Neurology -- Payer views

  • $ 2616
  • January 2018
  • 1 pages

When first line treatments for neurological diseases such as Parkinson’s Disease (PD) and Multiple Sclerosis (MS) have been around for years, it’s understandable that when something new is approved, ...

  • United States
  • European Union
  • Neurological Disorder
  • Industry analysis
  • Drug Approval

Medical Affairs Reputations: Psoriasis (EU5) 2018

  • $ 6948
  • February 2018
  • 1 pages

Compare 12 psoriasis medical affairs teams. See how your team stacks up to the market leader. In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck with at least ...

  • Spain
  • France
  • Monoclonal Antibody
  • Autoimmune Disease
  • Industry analysis

Medical Affairs Reputations: Type 2 Diabetes Mellitus [Orals] (EU5) 2018

  • $ 6948
  • February 2018
  • 1 pages

Compare 9 Type 2 Diabetes Mellitus medical affairs teams. See how your team stacks up to the market leader In the EU5, several of the Type 2 Diabetes Mellitus medical affairs teams we surveyed are running ...

  • Spain
  • France
  • Type 2 Diabetes
  • Industry analysis

Market Access Impact (EU5) [T2DM] (Injectables)

  • $ 5637
  • November 2017
  • 1 pages

Find out why doctors can’t prescribe your brand, and what you can do about it Market barriers affect just over a fifth of prescriptions for injectable treatments for Type 2 Diabetes Mellitus in the ...

  • Spain
  • France
  • Type 2 Diabetes
  • Insulin
  • Industry analysis

NPS+ (EU5) [MS]

  • $ 2844
  • November 2017
  • 1 pages

How does your multiple sclerosis brand stack up against the competition? There are various options available to EU5 neurologists to treat multiple sclerosis. Clearly some of these options are achieving ...

  • Europe
  • Spain
  • Neurological Disorder
  • Industry analysis

Market Access Impact (EU5) [RA]

  • $ 5637
  • November 2017
  • 1 pages

Eliminating market barriers could help one brand almost double its market share Market barriers have a modest but significant effect on rheumatoid arthritis (RA) prescriptions in the EU5. The brands ...

  • Spain
  • France
  • Monoclonal Antibody
  • Arthritis
  • Industry analysis

Market Access Impact (EU5) [T2DM] (Orals)

  • $ 2844
  • November 2017
  • 1 pages

Find out why doctors can’t prescribe your brand, and what you can do about it Market barriers affect just under a fifth of prescriptions for oral treatments for Type 2 Diabetes Mellitus in the EU5 ...

  • World
  • Spain
  • Type 2 Diabetes
  • Gliptins
  • Industry analysis

Medical Affairs Reputations (EU5) [Haemophilia A]

  • $ 6755
  • November 2017
  • 1 pages

How well does your haemophilia A medical affairs team performance compare with the rest? According to this latest survey of 150 haematologists across the EU5 (UK, France, Germany, Italy and Spain) the ...

  • Europe
  • Spain
  • Health Care Provider
  • Blood Disease
  • Industry analysis

Medical Affairs Reputations (EU5) [Haemophilia B]

  • $ 6755
  • November 2017
  • 1 pages

How well does your haemophilia B medical affairs team performance compare with the rest? According to this latest survey of 150 haematologists across the EU5 (UK, France, Germany, Italy and Spain) the ...

  • Europe
  • Spain
  • Blood Disease
  • Health Care Provider
  • Industry analysis

Medical Affairs Reputations (EU5) [Myeloma]

  • $ 6755
  • November 2017
  • 1 pages

How well does your multiple myeloma medical affairs team performance compare with the rest? According to this latest survey of 150 medical oncologists and haematologists across the EU5 (UK, France, ...

  • Europe
  • Spain
  • Health Care Provider
  • Cancer
  • Industry analysis

Type 2 Diabetes Mellitus: Update Bulletin #2 [March 2018]

  • $ 1151
  • March 2018
  • 1 pages

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the type 2 diabetes mellitus (T2DM) market, ...

  • World
  • North America
  • Insulin
  • Targeted Delivery
  • Industry analysis
  • Drug Approval

Value Added Services in Cardiometabolic Diseases -- Payer views

  • $ 2537
  • October 2017
  • 1 pages

Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post ...

  • United States
  • European Union
  • Pharmaceutical
  • Chronic Disease
  • Industry analysis

NPS+ (EU5) [Myeloma]

  • $ 2844
  • October 2017
  • 1 pages

How does your myeloma brand stack up against the competition? There are various options available to EU5 oncologists and haematologists to treat multiple myeloma. Clearly some of these options are achieving ...

  • Europe
  • Spain
  • Cancer
  • Industry analysis

Multiple Sclerosis: Update Bulletin #1 [February 2018]

  • $ 1151
  • February 2018
  • 1 pages

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved ...

  • Europe
  • United Kingdom
  • Neurological Disorder
  • Industry analysis

Bladder Cancer: Update Bulletin #2 [February 2018]

  • $ 1151
  • February 2018
  • 1 pages

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase ...

  • Europe
  • United States
  • Bladder Cancer
  • Hospital
  • Industry analysis

Medical Affairs Reputations (EU5) [Parkinson’s Disease]

  • $ 6755
  • October 2017
  • 1 pages

How well does your Parkinson’s Disease medical affairs team performance compare with the rest? According to this latest survey of 150 neurologists across the EU5 (UK, France, Germany, Italy and Spain) ...

  • Europe
  • Spain
  • Psychotic Disorder
  • Health Care Provider
  • Industry analysis
  • Practising Physicians

Medical Affairs Reputations (EU5) [RA]

  • $ 6755
  • October 2017
  • 1 pages

How well does your Rheumatoid Arthritis medical affairs team performance compare with the rest? According to this latest survey of 150 rheumatologists across the EU5 (UK, France, Germany, Italy and ...

  • Europe
  • Spain
  • Arthritis
  • Monoclonal Antibody
  • Industry analysis

Acute Myeloid Leukaemia:KOL Insight

  • $ 9000
  • February 2018
  • 1 pages

How will four newly approved therapies transform treatment of AML? For decades, there were no approved treatments for acute myeloid leukaemia (AML) other than chemotherapies. The past year has witnessed ...

  • United States
  • Germany
  • Chemotherapy
  • Leukemia
  • Industry analysis

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • February 2018
  • 1 pages

Can new biologics breathe fresh competition into the targeted asthma treatment landscape? The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Germany
  • Europe
  • Asthma
  • Respiratory Treatment
  • Industry analysis

Glioblastoma: KOL Insight

  • $ 9000
  • February 2018
  • 1 pages

Are novel therapies set to revolutionise glioblastoma? There has been little progress in the treatment of glioblastoma (GBM) for decades, and management of patients continues to remain challenging. Novel ...

  • United States
  • France
  • Therapy
  • Targeted Therapy
  • Industry analysis

NPS+ Type 2 Diabetes Mellitus EU5 2017

  • $ 2844
  • September 2017
  • 1 pages

Why are some EU5 diabetes brands standing out more than others? There are various options available to European diabetologists and primary care physicians to treat Type 2 Diabetes Mellitus (T2DM). Clearly ...

  • Europe
  • Type 2 Diabetes
  • Health Care Provider
  • Industry analysis

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on